Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Gilead's new HIV combo pill just got the FDA's stamp of approval. Bixlenvo combines bictegravir and lenacapavir into a once-daily oral tablet for adults with already-suppressed HIV. It's designed to simplify treatment for patients on complex multi-pill regimens, and Gilead expects it to hit shelves within days — at a wholesale cost of $4,595 for a 30-day supply.
The FDA has approved Bixlenvo, Gilead Sciences' once-daily oral combination pill for HIV-positive adults whose viral load is already suppressed. The drug pairs bictegravir — the backbone of the widely used Biktarvy — with lenacapavir, a capsid inhibitor that disrupts HIV's ability to replicate by targeting its protective shell. Patients start with a two-day loading dose of lenacapavir (Sunlenca) before transitioning to daily Bixlenvo.
The approval was backed by two late-stage trials showing Bixlenvo was as effective as complex multi-pill regimens and Biktarvy at maintaining viral suppression over 48 weeks. Gilead says the drug could be available within days of approval and is a key piece of its broader lenacapavir-centered HIV portfolio strategy.
Key Takeaways:
Why it matters: For patients managing drug-resistant HIV on cumbersome multi-pill regimens, Bixlenvo could meaningfully reduce pill burden without sacrificing efficacy — a real quality-of-life win in long-term HIV management.
